Arthur Yang
Principal investigator, leads Lynthera Corporation.
MaterialsFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$8.2MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $8.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 4, 2025 | NIH | SBIR Phase II Drug delivery platform for ocular allergy therapy | $900K | Lynthera Corporation |
| Aug 19, 2024 | NIH | SBIR Phase II Drug delivery platform for ocular allergy therapy | $900K | Lynthera Corporation |
| Aug 1, 2022 | NIH | SBIR Phase I Drug delivery platform for ocular allergy therapy | $300K | Lynthera Corporation |
| Jul 29, 2022 | NIH | SBIR Phase I Drug delivery platform for ocular allergy therapy | $300K | Lynthera Corporation |
| Mar 1, 2022 | NSF | SBIR Phase II SBIR Phase II:Mass Produced, Flexible Insulation for Non-Combustible Buildings and Other High-Temperature Applications | $1.7M | LIATRIS INC. |
| Jul 15, 2020 | NIH | SBIR Phase II Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $169K | Lynthera Corporation |
| Jun 1, 2020 | NSF | SBIR Phase I SBIR Phase I: Flexible high-temperature foam insulation materials mass produced using low-cost extrusion processing | $225K | LIATRIS INC. |
| May 20, 2019 | NIH | SBIR Phase II Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $754K | Lynthera Corporation |
| Jun 1, 2018 | NIH | SBIR Phase II Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $1.7M | Lynthera Corporation |
| May 31, 2018 | NIH | SBIR Phase II Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $755K | Lynthera Corporation |
| Sep 5, 2016 | NIH | SBIR Phase I Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $31K | Lynthera Corporation |
| Sep 1, 2016 | NIH | SBIR Phase I Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $256K | Lynthera Corporation |
| Apr 26, 2016 | NIH | SBIR Phase I Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection | $225K | Lynthera Corporation |
Peer ranks
Federal funding#5
Awards as PI#8
Patents#88
Companies
- Lynthera CorporationLeads (SEC Form D) · Medtech
- LIATRIS INC.Linked by awards · Materials
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.